Systemic Sclerosis (Scleroderma) – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23078IDB-L5

Select Item

Empower your strategies with our Systemic Sclerosis (Scleroderma) – Drugs In Development, 2024 report and make more profitable business decisions.

Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pain, joint pain and swelling, ulcers occurring on the fingertips, bloating, and diarrhea or constipation. Treatment includes antibiotics, pain relievers, and immunosuppressants.

The Systemic Sclerosis (Scleroderma) drugs in development market research report provide comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Systemic Sclerosis (Scleroderma)
Key Targets
· B Lymphocyte Antigen CD19; Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2; Bifunctional Glutamate/Proline tRNA Ligase; Interleukin 17A; Transforming Growth Factor Beta 1 Proprotein; Transforming Growth Factor Beta 3 Proprotein; Signal Transducer And Activator Of Transcription 3; Prostacyclin Receptor; Interferon Alpha/Beta Receptor 1; and Nuclear Factor Erythroid 2 Related Factor 2
Key Mechanisms of Action
· Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 Inhibitor; Bifunctional Glutamate/Proline tRNA Ligase Inhibitor; Interferon Alpha/Beta Receptor 1 Antagonist; Interleukin 17A Inhibitor; Nuclear Factor Erythroid 2 Related Factor 2 Activator; Signal Transducer And Activator Of Transcription 3 Inhibitor; Prostacyclin Receptor Agonist; Transforming Growth Factor Beta 3 Proprotein Inhibitor; Transforming Growth Factor Beta 1 Proprotein Inhibitor; and Transforming Growth Factor Beta 2 Proprotein Inhibitor
Key Routes of Administration
· Intravenous; Oral; Subcutaneous; Topical; Parenteral; Inhalational; Intravenous Drip; Intralymphatic; Hemodialysis; and Intradermal
Key Molecule Types
· Small Molecule; Monoclonal Antibody; Gene-Modified Cell Therapy; Cell Therapy; Fusion Protein; Monoclonal Antibody Conjugated; Recombinant Protein; Synthetic Peptide; Subunit Vaccine; and Peptide
Major Companies
· Genentech USA Inc; Mitsubishi Tanabe Pharma Corp; AegleStem Therapeutics; Boehringer Ingelheim International GmbH; Coya Therapeutics Inc; Pfizer Inc; Patagonia Pharmaceuticals LLC; PDX Pharmaceuticals Inc; Panorama Research Institute; and Opsidio LLC

Scope

  • Therapeutics in Development: Covering 109 molecules, with 101 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Systemic Sclerosis (Scleroderma) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Systemic Sclerosis (Scleroderma) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Systemic Sclerosis (Scleroderma) treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

4P-Pharma SAS
Accuitis Pharmaceuticals Inc
AegleStem Therapeutics
AISA Pharma Inc
Amgen Inc
AnaMar AB
Annji Pharmaceutical Co Ltd
APIE Therapeutics Inc
Arxx Therapeutics AS
AstraZeneca Plc
Astria Therapeutics Inc
Atlantic Healthcare Plc
aTyr Pharma Inc
Aurora Research Institute LLC
Avotres Inc
Bausch Health Companies Inc
Beijing Toll Biotech Co Ltd
Belarusian State Medical University
Biocad
Biogen Inc
Biomendics LLC
Blade Therapeutics Inc
Boehringer Ingelheim International GmbH
BriaCell Therapeutics Corp
Bristol-Myers Squibb Co
Cabaletta Bio Inc
Cantargia AB
Castle Creek Biosciences Inc
Celdara Medical LLC
Certa Therapeutics Pty Ltd
Chemomab Therapeutics Ltd
Chongqing Precision Biotech Co Ltd
Civi Biopharma Inc
Corvus Pharmaceuticals Inc
Coya Therapeutics Inc
CSL Ltd
Cumberland Pharmaceuticals Inc
Cureveda LLC
D&D Pharmatech Co Ltd
Daewoong Pharmaceutical Co Ltd
Drexel University
Edesa Biotech Inc
Eluciderm Inc
Eydis Bio Inc
F. Hoffmann-La Roche Ltd
FibroBiologics Inc
Foresee Pharmaceuticals Co Ltd
Friedrich-Alexander-University Erlangen-Nuremberg
Genentech USA Inc
Genrix (Shanghai) Biopharmaceutical Co Ltd
Gesynta Pharma AB
GNI Group Ltd
GSK plc
Guangzhou Henovcom Bioscience Co Ltd
Horizon Therapeutics Plc
HotSpot Therapeutics Inc
Huabo Biopharm (Shanghai) Co Ltd
Iltoo Pharma
ImmuneID Inc
Jiangsu Ruiyuan Biotechnology Co Ltd
Johnson & Johnson
Kymera Therapeutics Inc
Kyowa Kirin Co Ltd
Kyungpook National University
Kyverna Therapeutics Inc
Lassen Therapeutics 1 Inc
LightOx Ltd
Link Genomics Inc
Luminary Therapeutics Inc
Mallinckrodt Plc
Maruho Co Ltd
MDI Therapeutics Inc
Medsenic SAS
Merck & Co Inc
Mitsubishi Tanabe Pharma Corp
Nobelpharma Co Ltd
Ono Pharmaceutical Co Ltd
Opsidio LLC
Panorama Research Institute
Patagonia Pharmaceuticals LLC
PDX Pharmaceuticals Inc
Peptinov SAS
Pfizer Inc
Pharmosa Biopharm Inc
Queensland University of Technology
RadBio
Regeneron Pharmaceuticals Inc
Resolys Bio Inc
Ribomic Inc
Ribon Therapeutics Inc
Riptide Bioscience Inc
Rubedo Life Sciences Inc
Scopus BioPharma Inc
Seagen Inc
Shanghai YaKe Biotechnology Co Ltd
Signablok Inc
Takeda Pharmaceutical Co Ltd
Thirona Bio Inc
Timber Pharmaceuticals Inc
Tvardi Therapeutics Inc
University of California
University of Tennessee Health Science Center
Ventus Therapeutics Inc
Zura Bio Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Systemic Sclerosis (Scleroderma) reports
Pharmaceuticals
New
Evolution of GLP-1RAs - From Breakthrough to Growth: Strategic Intelligence
$3,450 | May 2026
Pharmaceuticals
New
Q1 2026 CRO Activity and Intel Report
$1,870 | May 2026
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, April 2026
$2,950 | May 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Systemic Sclerosis (Scleroderma) – Drugs In Development, 2024 in real time.

  • Access a live Systemic Sclerosis (Scleroderma) – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more